Soligenix, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ

21 Mar 2025

SNGX

10-K: Soligenix Reports Full Year 2024 Results, Highlights HyBryte Progress and Financial Outlook

Soligenix, a late-stage biopharmaceutical company, details its 2024 financial results and provides updates on its key development programs, including HyBryte for cutaneous T-cell lymphoma.

NASDAQ

15 Mar 2024

SNGX

Soligenix, INC

10-K: Soligenix Outlines Securities, Financials and Pipeline in 10-K Filing

Soligenix's 10-K filing details its authorized capital stock, ongoing clinical trials, and financial position, highlighting both opportunities and challenges.